3 Cannabis Stocks That Could Soar After Marijuana Rescheduling

Source Motley_fool

Key Points

  • Marijuana rescheduling can result in significant tax savings for multi-state operators (MSOs) in the U.S.

  • Three of the largest MSOs are Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis.

  • These are among the better-run cannabis companies in the entire industry, and they could be among the biggest winners from marijuana reform.

  • 10 stocks we like better than Curaleaf ›

The U.S. government recently announced it has rescheduled many medical marijuana products as Schedule III substances (down from Schedule I) and would also be looking at doing the same for recreational pot. For the cannabis industry, it marks a huge milestone. While it's not full-blown legalization or anything close to it, it's still significant progress. And for marijuana companies operating in the U.S., the change also means they'll be able to claim more expenses when filing their tax returns.

As a result, the main benefit from rescheduling will flow through to multi-state operations (MSOs). Three marijuana stocks that may have tremendous upside from rescheduling are Curaleaf Holdings (OTC: CURLF), Green Thumb Industries (OTC: GTBIF), and Trulieve Cannabis (OTC: TCNNF).

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Investor looking at stocks on a tablet.

Image source: Getty Images.

Curaleaf Holdings

One of the largest MSOs in the country is Curaleaf Holdings. It says it has "unparalleled reach across the United States," with a retail presence in 15 states and 159 locations as of Dec. 31, 2025. In addition, the company has also been expanding internationally into key markets such as Germany and the U.K., and plans to expand to Spain, France, and Turkey in the near future. It's a growth machine that looks to take advantage of opportunities in the marijuana industry.

Last year, the company generated nearly $1.3 billion in revenue, which was down 5% from the previous year. Cannabis companies have been struggling to find new growth opportunities, but as the industry expands, especially if greater reform is on the horizon, Curaleaf can be among the biggest winners from reform due to its vast presence and appetite for growth. For the 2025 fiscal year, the company estimates that it would have saved around $116 million on taxes related to 280e if rescheduling were implemented.

Shares of Curaleaf have spiked on rescheduling news, and they are now up 34% since the start of the year.

Green Thumb Industries

Another leading cannabis company is Green Thumb Industries, which has a comparable presence to Curaleaf. Green Thumb operates in 14 states and has 113 retail stores (as of March 6). Revenue has been rising, although its growth rate has slowed significantly in recent years due to a lack of new opportunities. But like Curaleaf, future reform could change that, and greater profitability may enable it to pursue more expansion.

In 2025, the company generated close to $1.2 billion in revenue, which was an increase of 3% from the previous year. What's noteworthy about Green Thumb is that, unlike many of its peers, its operations are already profitable. Last year, it generated net income of $114 million, which was up from $73 million in the previous year.

Earlier this year, CEO Ben Kovler estimated that Green Thumb would generate as much as $60 million per year in extra free cash flow as a result of rescheduling. Free cash can be critical in the industry to enable a cannabis giant such as Green Thumb to target more markets in the U.S., to help grow its sales.

Shares of Green Thumb have been rising in recent days, though on a year-to-date basis, the stock is up around just 3%. It could, however, have much more upside in the long run.

Trulieve Cannabis

Florida-based Trulieve Cannabis is another company poised to benefit significantly from rescheduling. It had 233 retail locations as of the end of 2025. However, the bulk of those are in its home state of Florida. It's not as diversified as the other companies on this list, but Trulieve is still a huge MSO and one that can benefit significantly from marijuana reform.

In 2025, it generated approximately $1.2 billion in revenue, which was virtually unchanged from the previous year. Although it posted a loss of $117 million for the year, it was profitable before taxes, with a pre-tax profit of nearly $92 million; its $208 provision for income taxes wiped that out entirely. Trulieve could stand to benefit significantly from rescheduling and a lower tax bill.

It's another pot stock that's been rallying in recent days, and it's now up more than 7% since the start of 2026. For long-term investors, it could be a compelling option to consider given its potential to rise far higher and expand into more states.

Should you buy stock in Curaleaf right now?

Before you buy stock in Curaleaf, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of April 28, 2026.

David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
What to Expect From NVIDIA Stock Price in April 2026?NVIDIA (NASDAQ: NVDA) stock price trades at $177.64 on the 2-day chart, up 5.31% over the past days but still down 6% year-to-date. April sits at a unique inflection for the stock. The Iran conflict c
Author  Beincrypto
Apr 08, Wed
NVIDIA (NASDAQ: NVDA) stock price trades at $177.64 on the 2-day chart, up 5.31% over the past days but still down 6% year-to-date. April sits at a unique inflection for the stock. The Iran conflict c
placeholder
Palantir Earnings Could Ignite AI Stocks Before NvidiaOne AI stock reports earnings on May 4, three weeks before Nvidia prints, and the technical setup is the most oversold it has looked in a year.Palantir (PLTR) closed above $143 on April 23, down about
Author  Beincrypto
Apr 24, Fri
One AI stock reports earnings on May 4, three weeks before Nvidia prints, and the technical setup is the most oversold it has looked in a year.Palantir (PLTR) closed above $143 on April 23, down about
placeholder
MicroStrategy’s Bitcoin Holdings Hit $63.46 Billion RecordStrategy’s Bitcoin (BTC) treasury climbed to a record $63.46 billion as of April 26, with the company holding 815,061 BTC across 107 purchase events at an average cost of $75,528 per coin.The treasury
Author  Beincrypto
Yesterday 02: 15
Strategy’s Bitcoin (BTC) treasury climbed to a record $63.46 billion as of April 26, with the company holding 815,061 BTC across 107 purchase events at an average cost of $75,528 per coin.The treasury
placeholder
MicroStrategy vs Tom Lee’s BitMine: Who Hits Target First?MicroStrategy and BitMine Immersion Technologies are racing toward different crypto accumulation targets. BitMine has pulled ahead. The Ether treasury is 16% short of its goal, while Strategy still tr
Author  Beincrypto
13 hours ago
MicroStrategy and BitMine Immersion Technologies are racing toward different crypto accumulation targets. BitMine has pulled ahead. The Ether treasury is 16% short of its goal, while Strategy still tr
placeholder
Ethereum Price Faces a New Risk and Potential Dip – Here’s WhyEthereum (ETH) price has broken down from the midline of its daily ascending channel after weeks of tightening volatility, opening the door to a slide toward $2,070 if support at $2,264 fails to hold.
Author  Beincrypto
13 hours ago
Ethereum (ETH) price has broken down from the midline of its daily ascending channel after weeks of tightening volatility, opening the door to a slide toward $2,070 if support at $2,264 fails to hold.
goTop
quote